AdvanSix ASIX · NYSE
$15.67 +1.49% (+$0.23)
Summary
33 / 100 · Bulios Score
What speaks for it
None of the indicators we track stands out on the positive side.
What to watch
- The company made a loss over the last 12 months.
- Earnings per share fell by 33% a year over the last 3 years.
- Repaying its net debt would take 8.0 years of operating profit.
- It passes only 2 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 5.6% a year over 5 years. Over the last 3 years it fell by 7.9% a year. Earnings per share fell by 33% a year over the last 3 years.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $17.7M.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
High, at risk- Yield
- 4.08%
You receive $0.64 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 3
- Hold 3
- Sell 0
Today's price within the analysts' price targets
The average target of $30.8 is 97% above today's price. 50% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Chemical Intermediates 39%
- Nylon Resins 32%
- Caprolactam 28%
By region
- UNITED STATES 86%
- Non-US 14%
Chemical Intermediates brings in 39% of revenue.
Segments in detail